Highlights

  • The therapy demonstrated a favourable tolerability profile, supported by dosimetry data and predominantly low-grade non-hematologic adverse events.
  • Lesion dosimetry analysis showed no meaningful differences in absorbed dose profiles across the various study cohorts.
  • No adverse drug–drug interactions were observed in treatment combinations involving TLX591-Tx.
  • The stock continues to trade above its Falling trendline breakout, supporting the ongoing bullish momentum.

Telix Pharmaceuticals Ltd (ASX: TLX) announced that Part 1 of its ProstACT Global Phase 3 study for TLX591-Tx (lutetium-177 rosopatamab tetraxetan) met primary objectives, confirming an acceptable safety and tolerability profile with no new safety signals. The study evaluated two doses administered 14 days apart alongside standard therapies in PSMA-positive metastatic castration-resistant prostate cancer patients previously treated with an ARPI.

Telix Pharmaceuticals Ltd Clinical Update Strengthens Investor Sentiment

Telix Pharmaceuticals Ltd reported encouraging progress in its ProstACT Global Phase 3 study evaluating TLX591-Tx for metastatic castration-resistant prostate cancer (mCRPC). The differentiated trial compares PSMA-targeted lutetium-177 rADC therapy combined with standard of care (SOC) versus SOC alone. Following successful completion of Part 1, which enrolled 36 patients across three treatment cohorts, the study has progressed to Part 2—a 2:1 randomized expansion in approved jurisdictions. Part 1 results will also be submitted to the U.S. Food and Drug Administration to support an Investigational New Drug amendment.

The therapy demonstrated an acceptable safety and tolerability profile, with most non-hematologic events limited to Grade 1–2 and hematologic effects considered manageable. Dosimetry results showed radiation exposure to key organs remained below safety limits, with sustained tumor uptake and no drug-drug interaction concerns observed.

Is Bullish Momentum Still Intact for Telix Pharmaceuticals Stock?

From a technical standpoint, TLX continues to trade above its key falling trendline breakout level, with strong trading volumes supporting the move and confirming sustained bullish momentum. The previously declining trendline has now transitioned into a crucial support zone, indicating a positive shift in market structure. As long as the stock remains above this support level, the broader uptrend is likely to stay intact, reinforcing constructive investor sentiment. This technical configuration highlights persistent buying interest in the stock and suggests that the near-term outlook remains favourable, with potential for further upside should the current momentum continue.

From a technical standpoint, TLX continues to trade above its 50-period Simple Moving Average (SMA), indicating sustained near-term strength and underlying buying support in the stock. The Relative Strength Index (RSI), currently at 57.82, reflects healthy bullish momentum while still leaving room for additional upside. On the resistance front, the stock faces an immediate hurdle near AUD 13.20, followed by a stronger supply zone around AUD 14.70. These levels could act as potential barriers where short-term profit-taking may emerge, potentially slowing the pace of further gains in the near term.

Positive Momentum Continues Following Strong Support Defence in TLX

Telix Pharmaceuticals Ltd (ASX: TLX) has strengthened investor sentiment, while the stock’s technical structure remains constructive. With prices holding above key support and momentum indicators staying positive, the near-term outlook appears favourable. A sustained move above key resistance levels could support further upside if buying interest continues.